Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics, Inc. (NASDAQ: FATE) announced the acceptance of one oral and four poster presentations for its induced pluripotent stem cell (iPSC) platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The oral presentation will focus on preclinical data for FT536, a CAR NK cell candidate targeting MICA/B proteins. Additionally, poster presentations will cover advancements in CAR T cell therapies for solid tumors. Fate plans to submit an IND application for FT536 in Q4 2021.

Fate Therapeutics announces the publication of preclinical data on FT538, its engineered iPSC-derived NK cell product candidate, showcasing enhanced anti-tumor activity compared to traditional NK cells. The data reveal that FT538 demonstrates significant functional persistence and superior serial killing capability. Key innovations include the knockout of CD38 and the introduction of an IL-15/IL-15R fusion protein. FT538 is currently undergoing Phase 1 trials for treating acute myeloid leukemia and multiple myeloma, positioning it as a promising off-the-shelf therapy in cancer immunotherapy.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on programmed cellular immunotherapies for cancer, announced its participation in several investor conferences in September 2021. Key events include the Virtual Wells Fargo Healthcare Conference on September 9, and the Morgan Stanley Annual Global Healthcare Conference on September 10. The company will also present at the H.C. Wainwright Conference on September 13, Baird’s Conference on September 15, Oppenheimer Summit on September 22, and Cantor Conference on September 29. Webcasts for these presentations can be found on their website.

Fate Therapeutics reported promising interim results from its FT596 and FT516 clinical programs for relapsed/refractory B-cell lymphoma. Notably, 71% of patients receiving FT596 achieved an objective response, with 50% achieving complete response (CR). In the FT516 program, 73% of patients achieved an objective response, with 55% reaching CR. Both treatments were well-tolerated, without significant adverse events. The company is initiating further dose-expansion cohorts and continuing to assess the treatment regimens' efficacy and safety.

Fate Therapeutics has made significant strides in the development of iPSC-derived therapies, with the first patient treated in the Phase 1 trial of FT819, a groundbreaking CAR T-cell therapy for relapsed/refractory ALL. Interim Phase 1 data for FT516 reveals that 73% of patients achieved objective responses in relapsed/refractory B-cell lymphoma. The company reported Q2 2021 revenue of $13.4 million, with R&D expenses at $48 million. Cash reserves stood at $845.1 million, indicating a solid financial position.

Fate Therapeutics, Inc. (NASDAQ: FATE) has appointed Yuan Xu, Ph.D., as an independent director to its Board of Directors. Dr. Xu has over 25 years of experience in the biopharmaceutical industry, with notable roles including CEO of Legend Biotech. She brings expertise in developing CAR T-cell therapies and will aid Fate in advancing its iPSC-derived NK and T-cell products into clinical development. The move is anticipated to strengthen the company's pipeline and manufacturing efforts as they progress towards commercial approval.

Fate Therapeutics (NASDAQ: FATE) announced the first patient treatment with FT819, an innovative off-the-shelf CAR T-cell therapy targeting CD19+ cancers. This Phase 1 clinical trial will evaluate three dosing regimens for patients with advanced B-cell leukemias and lymphomas. FT819 is derived from a clonal master iPSC line, promising consistent, mass production and broader patient availability. Key study objectives include safety assessments and determining optimal dosing for subsequent Phase 2 trials.

Fate Therapeutics (NASDAQ: FATE) announced a virtual event on August 19, 2021, to present interim Phase 1 clinical data for its FT596 and FT516 programs targeting relapsed/refractory B-cell lymphomas. The event will be accessible via the company’s website. Fate's iPSC product platform allows for the mass production of engineered cell therapies, enhancing treatment efficacy. FT516 is currently in trials as a standalone treatment for acute myeloid leukemia and in combination therapy, while FT596 targets B-cell antigens with promising preclinical results.

Fate Therapeutics (NASDAQ: FATE) has scheduled a conference call and live audio webcast for August 4, 2021, at 5:00 p.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. To participate, dial 800-773-2954 (toll-free) or 847-413-3731 (toll). The event will be accessible on the Company’s website under 'Events & Presentations.'

Fate Therapeutics is focused on developing programmed cellular immunotherapies for cancer, leveraging its proprietary iPSC product platform.